Marcel Jinih - Academia.edu (original) (raw)

Papers by Marcel Jinih

The Annals of The Royal College of Surgeons of England, 2017

INTRODUCTIONParathyroidectomy is the definitive treatment for primary hyperparathyroidism but the... more INTRODUCTIONParathyroidectomy is the definitive treatment for primary hyperparathyroidism but the intraoperative identification of adenomas is challenging. The aim of this study was to evaluate the utility of a radionuclide probe (RNP) in addition to intraoperative parathyroid hormone ( IOPTH) measurement as an intraoperative diagnostic adjunct in patients undergoing parathyroidectomy for primary hyperparathyroidism.METHODSThis was a retrospective cohort study of patients treated between 2004 and 2015 in a university affiliated teaching hospital. Patients were grouped into those with RNP use (RNP+) and those without (RNP-). The primary outcome measure was rate of operative failure, which included false positives. The diagnostic sensitivity and positive predictive value of both RNP and IOPTH were also evaluated.RESULTSA total of 298 patients were included in the study, 127 (42.6%) being in the RNP+ group and 171 (57.4%) in the RNP- group. The false positive rate for the RNP+ patients...

The Journal of Laryngology & Otology, 2022

ObjectiveThis study aimed to determine the awareness, otological symptoms and prevalence of exter... more ObjectiveThis study aimed to determine the awareness, otological symptoms and prevalence of external auditory canal exostoses in Irish cold-water athletes.MethodAn online and in person cross-sectional survey was undertaken with Irish cold-water athletes to explore athletes' awareness, known prevalence of external auditory canal exostoses and attitudes towards preventive measures.ResultsOf the 926 participants surveyed, 67.5 per cent were aware of external auditory canal exostoses. Triathletes reported the lowest awareness (39.9 per cent) among water athletes. A total of 9.7 per cent (n = 90) had previously been diagnosed with external auditory canal exostoses and 46.7 per cent (n = 42) were non-surfers. Ear symptoms were reported in 76 per cent of athletes. Otoscopic examinations showed that 23.7 per cent had external auditory canal exostoses, 3.6 per cent of whom were aware of their diagnosis.ConclusionThe majority of Irish surfing athletes are aware of external auditory canal ...

Anticancer Research, 2021

Background/Aim: Adjuvant therapeutic options are limited for triple negative breast cancer (TNBC)... more Background/Aim: Adjuvant therapeutic options are limited for triple negative breast cancer (TNBC). Thus, we evaluated the cytotoxic effects of the newly synthesized antineoplastic agent 1,4,5-Oxathiazinane-4,4-dioxide (OTD) on TNBC cells as a potential cancer therapeutic strategy. Materials and Methods: TNBC primary BT-20 and metastatic MDA-MB-231 cell lines were treated with increasing concentrations of OTD for various time periods to assess cell viability. Cell necrosis, apoptosis, necroptosis, autophagy, and ROS generation were evaluated using assay kits or specific inhibitors. Results: Treatment with OTD resulted in a dose-and time-dependent cell death of TNBC BT-20 and MDA-MB-231 cells. OTD also dose-dependently arrested TNBC cell proliferation. Notably, treatment with OTD induced both necrosis and apoptosis of TNBC cells, while the pan-caspase inhibitor Z-VAD-FMK partially attenuated OTD-induced cell death. Importantly, abrogated OTD-induced cell death was observed in the presence of the ROS scavenger N-acetylcysteine (NAC), whereas enhanced OTD-induced cell death was observed after the addition of the glutathione synthesis inhibitor BSO, indicating OTDinduced killing of TNBC cells via a reactive oxygen speciesdependent mechanism. Conclusion: OTD is strongly cytotoxic to both primary and metastatic TNBC cells, possibly by inducing multiple cell death pathways. Breast cancer is the commonest form of cancer in women accounting for approximately 29% of all new cancer cases and associated with 15% of cancer-related deaths (1). Of these, triple negative breast cancer (TNBC), characterised by lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor type 2 (HER2), is particularly aggressive and carries the worst prognosis. This is largely due to the lack of targeted molecular therapies for TNBC, which is in sharp contrast to ER-positive/PR-positive and HER2-positive subtypes. TNBC also has a poorer outcome after chemotherapy compared to other breast cancer subtypes, reflecting an intrinsically adverse prognosis and aggressive behaviour (2). Although anti-vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) monoclonal antibodies (e.g. bevacizumab), anti-VEGFR tyrosine kinase inhibitors (e.g. sunitinib and sorafenib), anti-endothelial growth factor receptor (EGFR) agents (e.g. cetuximab), poly (ADP ribose) polymerase (PARP) inhibitors (e.g. olaparib and veliparib), mammalian target of rapamycin (mTOR) inhibitors (e.g. everolimus) and Src tyrosine kinase inhibitor (e.g. dasatinib) have been studied in clinical trials, the results are variable (3). The most commonly used treatment regimens for TNBC in the clinical setting in many countries are a combination of anthracyclines, cyclophosphamide, and taxanes, while in some developing countries, the combination of cyclophosphamide-methrotrexate-5FU (CMF) is widely used for economic reasons (4, 5). In many of these trials, drug toxicity and severe side effects were a major source of concern, making the search for novel therapeutic agent(s) with reduced systemic toxicity very crucial. 1,4,5-oxathiazinane-4,4-dioxide (OTD) is a newly synthesized compound that has a ring structure similar to taurultam (Figure 1). Taurultam exists in equilibrium with taurolidine in aqueous solution, which is thought to play a crucial role in its mechanisms of action. Previous studies with taurolidine have shown that it exerts anti-inflammatory properties through inhibition of tumour necrosis factor-α (TNF-α), interleukin (IL)-1, IL-6, and IL-8, and is clinically 2247 This article is freely accessible online.

European Journal of Surgical Oncology (EJSO), 2017

Access to the full text of the published version may require a subscription.

Clinical Cancer Updates, 2008

The optimal duration and treatment strategies involving adjuvant endocrine therapy in early breas... more The optimal duration and treatment strategies involving adjuvant endocrine therapy in early breast cancer remained largely undetermined. As data emerge on the various modalities of treatment in both pre-and postmenopausal groups, debates, and discussions continue. Most studies to date focused on the 5-year duration of treatment consisting of mainly tamoxifen. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) study demonstrated that anastrozole is superior to tamoxifen and has become the mainstream treatment in postmenopausal women with early breast cancer, although the duration was arbitrarily set for 5 years, analogous to tamoxifen treatment. Several clinical trials, however, have emerged to support extended endocrine therapy as it becomes clear that the recurrence risk of breast cancer does not decrease beyond the initial 5 years of treatment. The advent of molecular signatures also plays an important role in the breast cancer profiling, and where available should be incorporated in the overall decision-making. Furthermore, side effects and noncompliance pose another issue in achieving an optimal treatment benefit. The decision-making as regards to extended endocrine treatment should therefore focus not only on the cancer biology alone but also include treatment side effects, assessment of risk of recurrence and patients' preference. In this review, we present an overview of the published studies to date as well as ongoing studies on the topic to better refine the options for adjuvant hormonal therapy. n

BMC Cancer, 2018

Background: Peri-operative inflammation has been extensively highlighted in cancer patients as de... more Background: Peri-operative inflammation has been extensively highlighted in cancer patients as detrimental. Treatment strategies to improve survival for cancer patients through targeting peri-operative inflammation have yet to be devised. Methods: We conducted a multi-centre, randomised controlled clinical trial using Taurolidine in non-metastatic colon cancer patients. Patients were randomly assigned to receive Taurolidine or a placebo. The primary endpoint for the study was the mean difference in day 1 IL-6 levels. Secondary clinical endpoints included rates of post-operative infections and tumor recurrence. Results: A total of 293 patients were screened for trial inclusion. Sixty patients were randomised. Twenty-eight patients were randomised to placebo and 32 patients to Taurolidine. IL-6 levels were equivalent on day 1 post-operatively in both groups. However, IL-6 levels were significantly attenuated over the 7 day study period in the Taurolidine group compared to placebo (p = 0.04). In addition, IL-6 levels were significantly lower at day 7 in the Taurolidine group (p = 0.04). There were 2 recurrences in the placebo group at 2 years and 1 in the Taurolidine group. The median time to recurrence was 19 months in the Placebo group and 38 months in the Taurolidine group (p = 0.27). Surgical site infection was reduced in the Taurolidine treated group (p = 0.09). Conclusion: Peri-operative use of Taurolidine significantly attenuated circulating IL-6 levels in the initial 7 day postoperative period in a safe manner. Future studies are required to establish the impact of IL-6 attenuation on survival outcomes in colon cancer.

Annals of Surgical Oncology, 2016

Background. Focused exploration (FE) and bilateral parathyroid exploration (BE) are the standard ... more Background. Focused exploration (FE) and bilateral parathyroid exploration (BE) are the standard surgical options for patients with primary hyperparathyroidism. However, the relative risk of recurrence, persistence, overall failure, reoperation, and any complications associated with either surgical approach is unclear. This study compared the outcomes and complication rates after FE and BE for patients with primary hyperparathyroidism. Methods. PubMed and Embase were searched for studies comparing these outcomes between FE and BE. A metaanalysis was performed using RevMan 5.3 software. Published data were pooled using the DerSimonian randomeffect model, and results were presented as odds ratio (OR) or mean difference with 95% confidence interval (CI). Results. A total of 12,743 patients from 19 studies were included in this meta-analysis. In comparison with BE, the FE arm had comparable rates of recurrence (OR 1.08; 95% CI 0.59-2.00; p = 0.80; n = 9 studies), persistence (OR 0.89; 95% CI 0.58-1.35; p = 0.58; n = 13), overall failure (OR 0.88; 95% CI 0.58-1.34; p = 0.56; n = 13), and reoperation (OR 1.05; 95% CI 0.25-4.32; p = 0.95, n = 4). The operative time was significantly shorter (mean difference =-39.86; 95% CI-53.05 to-26.84; p \ 0.01, n = 9), with a lower overall complication rate in Electronic supplementary material The online version of this article (